Navigation Links
R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
Date:9/10/2007

the most potent antiviral activity of any investigational nucleoside HCV polymerase inhibitor to date in doses suitable for progression into future combination studies," stated Dr. Michelle Berrey, Pharmasset's Vice President, Clinical Development & Chief Medical Officer. "Nucleosides are the cornerstone of antiviral therapeutic regimens due to their potency and safety profile. In addition, nucleosides have a significantly higher genetic barrier than non-nucleosides and protease inhibitors, which protects against drug-resistant mutations of HCV. We are pleased to be partnered with Roche for the development and commercialization of R7128. Roche continues to position itself as a company focused on expanding their market-leading HCV franchise to improve the lives of patients chronically infected with hepatitis C."

Conference Call

Pharmasset will host a conference call at 8:30AM (ET) on Monday, September 10, 2007 to discuss the R7128 Phase 1 study results.

Dial-in Information:

Domestic callers: 1 (800) 811-0667 (US/Canada)

International callers: 1 (913) 981-4901 (International)

Live audio of the conference call will be simultaneously broadcast over the internet via a webcast. To access the live webcast, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's corporate website at http://investor.pharmasset.com/events.cfm.

Please connect to the company's website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary to listen to the webcast. The archived replay of the webcast will be available on the Pharmasset website for two weeks following the conference call.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infe
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
4. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
5. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
6. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
7. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
8. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
9. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
10. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
11. Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015 ... for video, data and cloud computing operators has ... leading pharma giant for Internet of Things (IoT) ... applications offered on subscription model.      ... giant is striving for business innovations to make ...
(Date:7/30/2015)... , July 30, 2015  ResMed ... has signed a definitive agreement to acquire ... non-invasive ventilation and sleep-disordered breathing medical devices ... innovation and market reputation in China, combined with ResMed,s global leadership in sleep ... in China suffering ...
(Date:7/30/2015)... SAN DIEGO , July 30, 2015 /PRNewswire/ ... a medical device company and manufacturer of the ... it has entered into non-exclusive Development Agreements with ... generation Tandem insulin pumps with the Dexcom G5 ... "Integrating Tandem,s next generation pump platform with ...
Breaking Medicine Technology:Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3
... year,s flu season was marked by a particularly aggressive ... experts at Cardinal Health expect the vaccine to be ... The upcoming 2010-2011 flu season marks the first ... Practices (ACIP) has issued a universal vaccination recommendation, encouraging ...
... Biosciences, Inc. announced today the appointment of Merdad V. ... (Logo:   http://photos.prnewswire.com/prnh/20100513/LA04336LOGO ) (Logo: ... pleased to have Merdad as the new CEO of ... is returning to his role as Chairman of the ...
Cached Medicine Technology:Cardinal Health Helps Health Care Providers Prepare for 2010-2011 Flu Season 2Cardinal Health Helps Health Care Providers Prepare for 2010-2011 Flu Season 3Cardinal Health Helps Health Care Providers Prepare for 2010-2011 Flu Season 43-V Biosciences Appoints Merdad V. Parsey, MD, PhD, as Chief Executive Officer 2
(Date:8/1/2015)... ... ... “ reTXT ” was featured on NewsWatch as part of its monthly AppWatch, ... iOS, Android, and Windows. Joe Toohey, the host of AppWatch and technology expert, conducted ... any message including ones already sent. , While text messaging has more features than ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... When the ... stuff, Super-Sod debuted their new type of sod called Leisure Time(TM) zoysia . ... in process. , To commemorate introduction of this new type of sod, Super-Sod is ...
(Date:7/31/2015)... ... ... Aesthetics is New York’s only Thermage skin tightening pinnacle and black diamond award winner ... reduction in New York. Due to its unparalleled level of experience for these ... travel to New York to get their non-surgical skin tightening and body shaping procedures ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Sculpted Contours ... the CoolSmooth PRO this week. Zeltiq Aesthetics released this new applicator in the ... January 2014 for treating the outer thighs. The original applicator required a 2 ...
(Date:7/31/2015)... ... July 31, 2015 , ... Coco Libre announced today that their ... VIPs at the 2015 Vans US Open of Surfing, July 25 through August 2 ... “no added sugar” on the market, is a natural choice given the Open’s commitment ...
Breaking Medicine News(10 mins):Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2
... Symptoms of sepsis, such as cold hands, severe leg pain ... of bacterial meningitis, parents are being advised. // ... over after meningitis researchers identified new early-warning signs for parents, ... parents have been warned to look out for their child ...
... vegetable rich diet has been found to reduce the risk ... heart attack or strokes, according to a recent diet study. ... Imperial College London studied 4,680 people aged 40-59. They recommend ... a healthy lifestyle for prevention of high blood pressure and ...
... A report published in the January/February issue of General ... journal, says that most children's medicines have the potential ... sugar in them. // ,For example, antihistamine syrups ... low pH levels, which mean that they are high ...
... been found to work under the influence of alcohol ... Institute on Addictions (RIA) of the University of Buffalo. ... agencies were interviewed through telephone to obtain information about ... over the past 12 months. The study sample was ...
... assistance professor of psychology at south-western university and a graduate ... greater effect on the sexual behaviour of female rats. ... among the first to determine the effects of caffeine on ... into the relationship between caffeine and sex. ,The ...
... People worldwide are suffering from cancer. Virgin money life an insurance ... exclusively to cater the needs of cancer patients // . Richard ... cheaper when compared to other insurance cover programme. ... one out of three people suffer from cancer. Institute of cancer ...
Cached Medicine News:Health News:New warning signs for child meningitis 2Health News:Nearly 15% Of U.S. Workers Work Under The Influence Of Alcohol 2Health News:Cancer Cover Insurance “The Big V” Is Launched In U 2
Vaulted shank with guard....
... adjusted for perfect focus where it's needed ... This, along with Keeler's wide angle light ... the patient's pupil size, you will see ... Lithium-ion technology provides a longer life battery ...
... head design has been carefully considered with both ... head ensures the optimum viewing angle and the ... laser aligned for perfect focus where it is ... paper. This along with Keeler's wide angle ...
The Beta 200S combines Heine's patented aspherical optics (U.S. Pat. 4.963.014) and a single-step Rekoss disk with a range of 36 to +38 dpt. to provide perfectly-focused images even in cases of high ...
Medicine Products: